Home » Healthcare » Pharmaceuticals » Gastric Motility Disorder Drugs Market

Gastric Motility Disorder Drugs Market By Drug Type (Prokinetic Agents Segment, Antispasmodic Agents Segment, Acid Suppressors Segment) By Indication (Gastroparesis, Functional Dyspepsia, Gastroesophageal Reflux Disease (GERD), Irritable Bowel Syndrome(IBS), Other Motility Disorders) – Growth, Share, Opportunities & Competitive Analysis, 2018 – 2028

Price: $4999

Published: | Report ID: 22113 | Report Format : PDF

Market Insights

  • The global demand for gastric motility disorder drugs was valued at USD XX Million in 2022 and is expected to reach USD XX Million in 2030, growing at a CAGR of 4.9% between 2023 and 2030.
  • The prokinetic agents segment is the market leader by drug type, accounting for more than 40% of total value in 2022, while the antispasmodic agents segment is estimated to grow rapidly in the projection period.
  • The gastroparesis indication category is expected to expand quickly in the forecast period, while the gastroesophageal reflux disease (GERD) segment has the greatest market share in 2022.
  • The hospital pharmacies category dominated the market with 44% of the total revenue share by distribution channel. In contrast, the retail and online pharmacies category will expand fastest during the projected time frame.
  • North America is fueling the growth of the gastric motility disorder drugs industry with over one-third share in 2022, while Asia Pacific and Europe collectively accounted for just under 54% share in 2022. Europe held over 20% market revenue share in 2022.
  • A sizable section of the population is affected by gastric motility problems, such as gastroparesis and functional dyspepsia, which results in an expanding patient base.
  • Prokinetic agents, antiemetics, and medications to manage symptoms such as nausea and vomiting are commonly prescribed for gastric motility disorders.
  • Older persons are more likely to have stomach motility problems, and as the world’s population ages, there is a rising demand for medications to treat these illnesses.

Executive Summary

Market Definition

The gastric motility disorder drugs market refers to the pharmaceutical sector focused on the development, manufacturing, marketing, and distribution of medications and therapeutic agents designed to diagnose, manage, or treat gastric motility disorders. These disorders involve abnormalities in the movement and function of the stomach and gastrointestinal tract, leading to symptoms such as delayed emptying of the stomach (gastroparesis), indigestion, nausea, vomiting, and abdominal discomfort. The market encompasses a range of drugs, including prokinetic agents, antiemetics, and other medications aimed at alleviating symptoms, improving gastric emptying, and enhancing the overall quality of life for individuals affected by gastric motility disorders. It is driven by factors such as increasing disease prevalence, advancements in treatment options, and ongoing research & development efforts to address these challenging conditions.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

CTA Design Element 3

Market Overview

The global gastric motility disorder drugs market has witnessed rapid growth in recent years and is expected to grow at a CAGR of 4.9% between 2023 and 2030. The market was valued at USD XX million in 2022 and is expected to reach USD XX million in 2030.

Food moves through the gastrointestinal tract by peristalsis, a series of muscle contractions known as gastric motility (or gastrointestinal motility). These contractions are irregular in those who have a gastric motility disorder, which inhibits food from moving normally into the intestines. These conditions can also cause gastroesophageal reflux disease (GERD), breathing difficulty, stomach problems, severe constipation or diarrhea, abdominal pain, vomiting, and bloating. Thus, demand for drugs for the treatment of gastric motility disorders is expected to rise in the coming years, fueling market growth.

The existence of gastric motility disorder is also associated with the prevalence of digestive difficulties and the illness known as irritable bowel syndrome (IBS). The global market for digestive health enzymes is also predicted to develop as a result of the aging population, which is more prone to gastrointestinal issues, and the shift in population priorities towards preventative health management. Age-related decreases in digestive enzyme output are commonly the cause of poor digestion, decreased food intake, frequent gastric discomfort, and a range of other gastrointestinal disorders. Another factor that is expected to propel market expansion is the effectiveness of these pharmaceuticals in treating a variety of conditions, such as multiple organ failure, hepatitis, and stomach cancer.

Segmentation by Drug Type

  • The antispasmodic agents segment is projected to exhibit the highest CAGR in the coming years due to their effectiveness in alleviating gastric motility disorder symptoms, such as abdominal pain and cramps. These drugs offer relief to a broad patient population.
  • The prokinetic agents segment dominates the market share with over 40% in 2022. Their ability to stimulate gastric motility and improve stomach emptying makes them a cornerstone in the treatment of these disorders.

Segmentation by Indication

  • The gastroesophageal reflux disease (GERD) segment is projected to register the highest CAGR as the prevalence of GERD-related gastric motility disorders continues to rise globally. Effective management of GERD is crucial in addressing related motility issues.
  • The gastroparesis segment led the market with over 30% share in 2022. This segment’s prominence is attributed to the high prevalence of gastroparesis as a standalone disorder and its frequent association with other gastrointestinal conditions.

Segmentation by Distribution Channel

  • Retail and online pharmacies are projected to exhibit the highest CAGR. The convenience of obtaining prescription medications through these channels and the increasing popularity of online pharmacies contribute to this growth.
  • Hospital pharmacies currently lead the market share with over 44% in 2022. These pharmacies play a key role in providing immediate access to medications for patients with severe gastric motility disorders who require hospitalization.

Segmentation by Region

  • North America has a robust healthcare infrastructure and advanced research capabilities, making it a highly profitable region. It held over one-third of the global gastric motility disorder drugs market share in 2022, with pharmaceutical companies benefiting from extensive research collaborations and patient access.
  • The Asia Pacific and Europe regions collectively contribute to nearly 54% of the market share. While Europe holds a substantial revenue share of over 20% in the same year, the Asia Pacific region displays significant potential for growth, driven by increasing awareness and improving healthcare access.
  • The rest of the world, encompassing regions like Latin America, the Middle East, and Africa, contributes to the remaining demand for gastric motility disorder drugs. These regions represent emerging markets with evolving healthcare systems and offer growth opportunities for pharmaceutical companies expanding their global reach.

The global market for gastric motility disorder drugs has been experiencing steady growth due to an increase in the prevalence of these disorders, improved diagnostics, and rising awareness.

North America dominates the global gastric motility disorder drugs market. The region has a high prevalence of gastric motility disorders, attributed in part to lifestyle factors and an aging population, which has resulted in a substantial patient pool. North America also benefits from a well-developed healthcare infrastructure and advanced diagnostic capabilities, facilitating early diagnosis and treatment of these disorders. Besides, the presence of numerous pharmaceutical companies, research institutions, and clinical trial centers fosters innovation in drug development and drives the availability of a wide range of treatment options. Moreover, a favorable regulatory environment and strong healthcare reimbursement systems in countries like the United States further support market growth by incentivizing research and the introduction of new therapies.

Over the projection period, the Asia Pacific is estimated to be the fastest-growing market for gastric motility disorder drugs. The region is experiencing significant demographic shifts, with a growing aging population and an increasing incidence of lifestyle-related diseases like diabetes, which are known contributors to gastric motility disorders. There is also a rising awareness of gastrointestinal health and an increased willingness among patients to seek medical care and diagnosis for such conditions. Moreover, ongoing improvements in healthcare infrastructure, increased access to healthcare services, and advancements in diagnostic capabilities in countries across the Asia Pacific are facilitating early detection and treatment. Furthermore, pharmaceutical companies are recognizing the growth potential in this region. They are actively expanding their presence, conducting clinical trials, and launching tailored marketing strategies to meet the rising demand for gastric motility disorder drugs.

Key Highlights of the Report

The global gastric motility disorder drugs market is segmented by drug type, indication, distribution channel, and region. Prokinetic agents dominate the global market, while antispasmodic agents are projected to exhibit significant growth. Gastroparesis is the leading indication, while gastroesophageal reflux disease (GERD) is expected to grow rapidly. Hospital pharmacies are the primary distribution channel, with retail and online pharmacies showing strong potential.

The global gastric motility disorder drugs market is primarily driven by the increasing prevalence of these disorders, particularly among aging populations, coupled with emerging awareness and diagnosis. Advancements in diagnostic techniques, including wireless motility capsules and high-resolution manometry, contribute to early detection and treatment. Emerging biological therapies and personalized medicine approaches offer innovative treatment options. Expansion into emerging markets in Asia-Pacific and Latin America presents growth opportunities. However, limited treatment options and complex regulatory approval processes serve as restraints, demanding innovative solutions to meet patient needs and navigate regulatory hurdles effectively.

North America currently dominates the global gastric motility disorder drugs market, driven by its strong healthcare infrastructure, extensive research capabilities, and high prevalence of related conditions, particularly gastroesophageal reflux disease (GERD). On the other hand, the Asia-Pacific region presents a promising growth landscape fueled by changing demographics, improving healthcare access, and increasing awareness of gastric motility disorders. Pharmaceutical companies are strategically expanding into this region, conducting clinical trials, and customizing marketing approaches to tap into the rising demand for gastric motility disorder drugs, positioning it as a potential growth hotspot in the global market.

What Are The Main Drivers Of The Global Gastric Motility Disorder Drugs Market?

The main drivers of the global gastric motility disorder drugs market include the increasing prevalence of gastric motility disorders worldwide, particularly among aging populations, as well as the rising awareness and diagnosis of these conditions. Besides, advancements in diagnostic techniques and a growing emphasis on patient-centric care are driving the demand for more effective drugs. Ongoing research and innovation in drug development, including biological therapies and personalized medicine approaches, further contribute to market growth. High healthcare costs associated with managing gastric motility disorders, coupled with the economic burden of these conditions, are compelling the healthcare industry to seek cost-effective treatments and therapies, creating opportunities for pharmaceutical companies in this niche market.

What Are The Major Challenges Faced By The Global Gastric Motility Disorder Drugs Market?

The major challenges faced by the global gastric motility disorder drugs market include the need for more comprehensive and effective treatment options, as existing drugs often offer partial relief and can have side effects. Regulatory hurdles in drug development, stemming from the complexity of conducting clinical trials specific to gastric motility disorders, can lead to delays in bringing new therapies to market. Moreover, the niche nature of this market presents challenges in terms of patient recruitment for clinical trials and the limited patient pool, affecting the potential for profitability. High healthcare costs associated with managing severe cases of gastric motility disorders, coupled with limited insurance coverage and reimbursement options, also pose challenges for both patients and pharmaceutical companies in this space. In addition, market consolidation and increased competition may impact pricing and market access for existing and new drugs.

What Are The Growth Opportunities In The Global Gastric Motility Disorder Drugs Market?

The global gastric motility disorder drugs market offers promising growth opportunities driven by factors such as the increasing prevalence of gastric motility disorders due to aging populations and lifestyle-related conditions. Advanced therapeutic approaches, including biologics and personalized medicine, hold the potential to deliver more effective and targeted treatments. Expanding into emerging markets, especially in regions with developing healthcare infrastructure, presents avenues for market expansion. Also, advancements in diagnostic tools and techniques enhance early diagnosis and precise treatment planning, ultimately improving patient outcomes and fueling market growth. The ongoing emphasis on patient-centric care and the need for cost-effective therapies further underscores the growth potential in this niche pharmaceutical market.

Market Drivers

Several factors drive the global gastric motility disorder drugs market. The following are the key drivers of the global gastric motility disorder drugs market:

Increasing Prevalence of Gastric Motility Disorders

One of the primary drivers of the global gastric motility disorder drugs market is the rising prevalence of gastric motility disorders worldwide. These disorders, including gastroparesis and functional dyspepsia, are becoming more common due to various factors. Aging populations are more susceptible to these conditions, and as the global population continues to age, the number of individuals affected by gastric motility disorders is expected to increase. Lifestyle-related factors such as obesity and diabetes also contribute to the higher incidence of these disorders. As more people are diagnosed with gastric motility disorders, there is an escalating demand for effective drugs to manage their symptoms and improve their quality of life. According to a multinational survey conducted by the American Gastroenterological Association on 73,076 respondents, more than 40% of persons worldwide have Functional Gastrointestinal Disorders (FGIDs), which have a substantial influence on their healthcare utilization and quality of life. This growing patient population provides a considerable market for pharmaceutical companies to target.

Market Restraints

The global gastric motility disorder drugs market faces challenges that may hinder its growth. These include the following:

Limited Treatment Options

One of the key restraints in the global gastric motility disorder drugs market is the limited number of available treatment options. Currently, the drugs approved for gastric motility disorders, such as prokinetic agents and antiemetics, provide symptomatic relief but may not address the underlying causes of these disorders. Moreover, some patients do not respond well to existing medications or may experience side effects that limit their use. The lack of diverse and highly effective treatment choices poses a challenge, as it leaves many patients with limited therapeutic alternatives. Pharmaceutical companies face hurdles in developing novel drugs due to the complex nature of gastric motility disorders and the stringent regulatory requirements for new therapies. This limitation restricts the market’s ability to meet the diverse needs of patients and may lead to unmet medical needs within the patient population.

Opportunities

The global gastric motility disorder drugs market offers significant growth opportunities. These include the following:

Emerging Biologic Therapies and Personalized Medicines

One major opportunity in the global gastric motility disorder drugs market is the development and adoption of biologic therapies and personalized medicine approaches. Biologics, such as neurostimulation and cell-based therapies, are emerging as potential treatment options for severe cases of gastric motility disorders. These therapies offer the advantage of being more targeted and tailored to the individual patient’s needs, addressing the specific underlying causes of their disease. Moreover, personalized medicine approaches can help identify patient subgroups that may respond better to certain drugs or therapies based on their genetic or physiological characteristics. As research in this area continues to advance, there is substantial potential for pharmaceutical companies to develop innovative and highly effective treatments, providing patients with improved outcomes and quality of life.

Competitive Landscape

Key Players

The competitive landscape of the global gastric motility disorder drugs market is characterized by a mix of large pharmaceutical companies, biotechnology firms, and emerging biotech striving to offer effective treatment solutions. The following are some of the top market players and their market shares:

  • Abbott
  • Janssen Pharmaceuticals NV
  • Sun Pharmaceutical Industries Ltd
  • Cipla Inc
  • Gilead Sciences Inc
  • Biogen
  • Organon Group of Companies
  • AbbVie Inc
  • AstraZeneca
  • Salix Pharmaceuticals
  • Takeda Pharmaceutical Company Ltd
  • Pfizer Inc
  • Bayer AG
  • Others

These entities are engaged in the development and marketing of medications and therapies to address gastric motility disorders. The market also includes generic drug manufacturers, which offer cost-effective alternatives to brand-name drugs. As R&D efforts continue to focus on innovative treatment approaches, the landscape may witness increased collaboration between pharmaceutical companies, research institutions, and academic organizations, leading to a dynamic and evolving competitive environment. Additionally, regulatory factors and the ability to navigate the approval process for new drugs play a key role in shaping the competitive dynamics of this niche market.

In October 2020, Evoke Pharma Inc. and EVERSANA reported the commercial introduction of Gimoti (metoclopramide) nasal spray for the treatment of acute and recurring diabetic gastroparesis in adults.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Summary of Key Findings

  • Factors driving market growth include an aging population, increased prevalence of lifestyle-related disorders (like diabetes), and a growing awareness of gastric motility disorders and their impact on quality of life.
  • Market segmented by drug type, indication, distribution channel, and region.
  • Gastroparesis and gastroesophageal reflux disease (GERD) are among the prevalent indications, with gastroparesis leading in terms of market share.
  • Hospital pharmacies distribution channels lead the market, while retail and online pharmacies are expected to show the highest CAGR.
  • North America holds a significant share due to a strong healthcare infrastructure, with Asia Pacific and Europe collectively contributing to a substantial portion of the market.
  • Pharmaceutical companies such as Takeda Pharmaceutical, Valeant Pharmaceuticals, and Allergan (now part of AbbVie) have been prominent players in this market.
  • Challenges in this market include limited treatment options, side effects of certain drugs, and the need for more effective therapies for refractory cases.

Future Outlook

  • Emerging economies, especially in Asia-Pacific and Latin America, are becoming important growth markets for gastric motility disorder drugs due to changing demographics and healthcare infrastructure development.
  • The economic burden of gastric motility disorders is significant, with high healthcare costs associated with hospitalizations, emergency room visits, and long-term management, driving the need for cost-effective treatments.
  • Biologic therapies, including neurostimulation and cell-based therapies, are emerging as potential treatment options for severe cases of gastric motility disorders.
  • The use of telemedicine and remote monitoring technologies is expanding, allowing healthcare providers to monitor and manage patients with gastric motility disorders more effectively, especially during the ongoing COVID-19 pandemic.

Segmentation

  • By Drug Type
    • Prokinetic Agents Segment
    • Antispasmodic Agents Segment
    • Acid Suppressors Segment
  • By Indication
    • Gastroparesis
    • Functional Dyspepsia
    • Gastroesophageal Reflux Disease (GERD)
    • Irritable Bowel Syndrome (IBS)
    • Other Motility Disorders
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region
    • North America
      • The U.S.
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • The U.K.
      • Italy
      • Spain
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • India
      • South Korea
      • South-east Asia
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Argentina
      • Rest of Latin America
    • Middle East & Africa
      • GCC Countries
      • South Africa
      • Rest of the Middle East and Africa

Adjacent Markets

Several adjacent markets have high revenue growth opportunities in the gastric motility disorder drugs market. The key adjacent markets for gastric motility disorder drugs market –

1. Preface

1.1. Report Description

1.1.1. Purpose of the Report

1.1.2. Target Audience

1.1.3. USP and Key Offerings

1.2. Research Scope

1.3. Market Introduction

 

2. Executive Summary

2.1. Market Snapshot: Global Gastric Motility Disorder Drugs Market

2.1.1. Global Gastric Motility Disorder Drugs Market, By Drug Type

2.1.2. Global Gastric Motility Disorder Drugs Market, By Indication

2.1.3. Global Gastric Motility Disorder Drugs Market, By Distribution Channel

2.1.4. Global Gastric Motility Disorder Drugs Market, By Region

2.2. Insights from Primary Respondents

 

3. Market Dynamics & Factors Analysis

3.1. Introduction

3.1.1. Global Gastric Motility Disorder Drugs Market Value, 2017-2030, (US$ Mn)

3.1.2. Y-o-Y Growth Trend Analysis

3.2. Market Dynamics

3.2.1. Gastric Motility Disorder Drugs Market Drivers

3.2.2. Gastric Motility Disorder Drugs Market Restraints

3.2.3. Gastric Motility Disorder Drugs Market Opportunities

3.2.4. Major Gastric Motility Disorder Drugs Industry Challenges

3.3. Growth and Development Patterns

3.4. Investment Feasibility Analysis

3.5. Market Opportunity Analysis

3.5.1. Drug Type

3.5.2. Indication

3.5.3. Distribution Channel

3.5.4. Geography

 

4. Market Competitive Landscape Analysis

4.1. Company Market Share Analysis, 2022

4.1.1. Global Gastric Motility Disorder Drugs Market: Company Market Share, Value 2022

4.1.2. Global Gastric Motility Disorder Drugs Market: Top 6 Company Market Share, Value 2022

4.1.3. Global Gastric Motility Disorder Drugs Market: Top 3 Company Market Share, Value 2022

4.2. Global Gastric Motility Disorder Drugs Market: Company Revenue Share Analysis, 2022

4.3. Company Assessment Metrics, 2022

4.3.1. Stars

4.3.2. Emerging Leaders

4.3.3. Pervasive Players

4.3.4. Participants

4.4. Startups/SMEs Assessment Metrics, 2022

4.4.1. Progressive Companies

4.4.2. Responsive Companies

4.4.3. Dynamic Companies

4.4.4. Starting Blocks

4.5. Strategic Development

4.5.1. Acquisition and Mergers

4.5.2. New Product Launch

4.5.3. Regional Expansion

4.5.4. Partnerships

4.6. Key Player Product Matrix

4.7. Potential for New Players in the Global Gastric Motility Disorder Drugs Market

 

5. Premium Insights

5.1. STAR (Situation, Task, Action, Results) Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Threat of New Entrants

5.2.2. Bargaining Power of Buyers/Consumers

5.2.3. Bargaining Power of Suppliers

5.2.4. Threat of Substitute Types

5.2.5. Intensity of Competitive Rivalry

5.3. PESTEL Analysis

5.3.1. Political Factors

5.3.2. Economic Factors

5.3.3. Social Factors

5.3.4. Technological Factors

5.3.5. Environmental Factors

5.3.6. Legal Factors

5.4. Key Market Trends

5.4.1. Demand Side Trends

5.4.2. Supply Side Trends

5.5. Value Chain Analysis

5.6. Technology Analysis

5.6.1. Research and development in the global market

5.6.2. Patent Analysis

5.6.3. Emerging technologies and their potential disruption to the market

5.7. Consumer Behaviour Analysis

5.7.1. Consumer Preferences and Expectations

5.7.2. Factors Influencing Consumer Buying Decisions

5.7.2.1. North America

5.7.2.2. Europe

5.7.2.3. Asia Pacific

5.7.2.4. Latin America

5.7.2.5. Middle East and Africa

5.7.3. Consumer Pain Points

5.8. Analysis and Recommendations

5.9. Adjacent Market Analysis

 

6. Market Positioning of Key Players, 2022

6.1. Company market share of key players, 2022

6.2. Competitive Benchmarking

6.3. Market Positioning of Key Vendors

6.4. Geographical Presence Analysis

6.5. Major Strategies Adopted by Key Players

6.5.1. Key Strategies Analysis

6.5.2. Mergers and Acquisitions

6.5.3. Partnerships

6.5.4. Product Launch

6.5.5. Geographical Expansion

6.5.6. Others

 

7. Impact Analysis of COVID-19 and Russia – Ukraine War on Gastric Motility Disorder Drugs Market

7.1. Ukraine-Russia War Impact

7.1.1. Uncertainty and Economic Instability

7.1.2. Supply chain disruptions

7.1.3. Regional market shifts

7.1.4. Shift in government priorities

7.2. COVID-19 Impact Analysis

7.2.1. Supply Chain Disruptions

7.2.2. Demand Fluctuations

7.2.3. Shift in Product Mix

7.2.4. Reduced Industrial Activity

7.2.5. Regional Impact Analysis

7.2.5.1. North America

7.2.5.2. Europe

7.2.5.3. Asia Pacific

7.2.5.4. Latin America

7.2.5.5. Middle East and Africa

 

8. Global Gastric Motility Disorder Drugs Market, By Drug Type

8.1. Global Gastric Motility Disorder Drugs Market Overview, by Drug Type

8.1.1. Global Gastric Motility Disorder Drugs Market Revenue Share, By Drug Type, 2022 Vs 2030 (in %)

8.2. Prokinetic Agents Segment

8.2.1. Global Gastric Motility Disorder Drugs Market, By Prokinetic Agents Segment, By Region, 2017-2030 (US$ Mn)

8.2.2. Market Dynamics for Prokinetic Agents Segment

8.2.2.1. Drivers

8.2.2.2. Restraints

8.2.2.3. Opportunities

8.2.2.4. Trends

8.3. Antispasmodic Agents Segment

8.3.1. Global Gastric Motility Disorder Drugs Market, By Antispasmodic Agents Segment, By Region, 2017-2030 (US$ Mn)

8.3.2. Market Dynamics for Antispasmodic Agents Segment

8.3.2.1. Drivers

8.3.2.2. Restraints

8.3.2.3. Opportunities

8.3.2.4. Trends

8.4. Acid Suppressors Segment

8.4.1. Global Gastric Motility Disorder Drugs Market, By Acid Suppressors Segment, By Region, 2017-2030 (US$ Mn)

8.4.2. Market Dynamics for Acid Suppressors Segment

8.4.2.1. Drivers

8.4.2.2. Restraints

8.4.2.3. Opportunities

8.4.2.4. Trends

 

9. Global Gastric Motility Disorder Drugs Market, By Indication

9.1. Global Gastric Motility Disorder Drugs Market Overview, by Indication

9.1.1. Global Gastric Motility Disorder Drugs Market Revenue Share, By Indication, 2022 Vs 2030 (in %)

9.2. Gastroparesis

9.2.1. Global Gastric Motility Disorder Drugs Market, By Gastroparesis, By Region, 2017-2030 (US$ Mn)

9.2.2. Market Dynamics for Gastroparesis

9.2.2.1. Drivers

9.2.2.2. Restraints

9.2.2.3. Opportunities

9.2.2.4. Trends

9.3. Functional Dyspepsia

9.3.1. Global Gastric Motility Disorder Drugs Market, By Functional Dyspepsia, By Region, 2017-2030 (US$ Mn)

9.3.2. Market Dynamics for Functional Dyspepsia

9.3.2.1. Drivers

9.3.2.2. Restraints

9.3.2.3. Opportunities

9.3.2.4. Trends

9.4. Gastroesophageal Reflux Disease (GERD)

9.4.1. Global Gastric Motility Disorder Drugs Market, By Gastroesophageal Reflux Disease (GERD), By Region, 2017-2030 (US$ Mn)

9.4.2. Market Dynamics for Gastroesophageal Reflux Disease (GERD)

9.4.2.1. Drivers

9.4.2.2. Restraints

9.4.2.3. Opportunities

9.4.2.4. Trends

9.5. Irritable Bowel Syndrome (IBS)

9.5.1. Global Gastric Motility Disorder Drugs Market, By Irritable Bowel Syndrome (IBS), By Region, 2017-2030 (US$ Mn)

9.5.2. Market Dynamics for Irritable Bowel Syndrome (IBS)

9.5.2.1. Drivers

9.5.2.2. Restraints

9.5.2.3. Opportunities

9.5.2.4. Trends

9.6. Other Motility Disorders

9.6.1. Global Gastric Motility Disorder Drugs Market, By Other Motility Disorders, By Region, 2017-2030 (US$ Mn)

9.6.2. Market Dynamics for Other Motility Disorders

9.6.2.1. Drivers

9.6.2.2. Restraints

9.6.2.3. Opportunities

9.6.2.4. Trends

 

10. Global Gastric Motility Disorder Drugs Market, By Distribution Channel

10.1. Global Gastric Motility Disorder Drugs Market Overview, by Distribution Channel

10.1.1. Global Gastric Motility Disorder Drugs Market Revenue Share, By Distribution Channel, 2022 Vs 2030 (in %)

10.2. Hospital Pharmacies

10.2.1. Global Gastric Motility Disorder Drugs Market, By Hospital Pharmacies, By Region, 2017-2030 (US$ Mn)

10.2.2. Market Dynamics for Hospital Pharmacies

10.2.2.1. Drivers

10.2.2.2. Restraints

10.2.2.3. Opportunities

10.2.2.4. Trends

10.3. Retail Pharmacies

10.3.1. Global Gastric Motility Disorder Drugs Market, By Retail Pharmacies, By Region, 2017-2030 (US$ Mn)

10.3.2. Market Dynamics for Retail Pharmacies

10.3.2.1. Drivers

10.3.2.2. Restraints

10.3.2.3. Opportunities

10.3.2.4. Trends

10.4. Online Pharmacies

10.4.1. Global Gastric Motility Disorder Drugs Market, By Online Pharmacies, By Region, 2017-2030 (US$ Mn)

10.4.2. Market Dynamics for Online Pharmacies

10.4.2.1. Drivers

10.4.2.2. Restraints

10.4.2.3. Opportunities

10.4.2.4. Trends

 

11. Global Gastric Motility Disorder Drugs Market, By Region

11.1. Global Gastric Motility Disorder Drugs Market Overview, by Region

11.1.1. Global Gastric Motility Disorder Drugs Market, By Region, 2022 vs 2030 (in%)

11.2. Drug Type

11.2.1. Global Gastric Motility Disorder Drugs Market, By Drug Type, 2017-2030 (US$ Mn)

11.3. Indication

11.3.1. Global Gastric Motility Disorder Drugs Market, By Indication, 2017-2030 (US$ Mn)

11.4. Distribution Channel

11.4.1. Global Gastric Motility Disorder Drugs Market, By Distribution Channel, 2017-2030 (US$ Mn)

 

12. North America Gastric Motility Disorder Drugs Market Analysis

12.1. Overview

12.1.1. Market Dynamics for North America

12.1.1.1. Drivers

12.1.1.2. Restraints

12.1.1.3. Opportunities

12.1.1.4. Trends

12.2. North America Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2030(US$ Mn)

12.2.1. Overview

12.2.2. SRC Analysis

12.3. North America Gastric Motility Disorder Drugs Market, by Indication, 2017-2030(US$ Mn)

12.3.1. Overview

12.3.2. SRC Analysis

12.4. North America Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2030(US$ Mn)

12.4.1. Overview

12.4.2. SRC Analysis

12.5. North America Gastric Motility Disorder Drugs Market, by Country, 2017-2030 (US$ Mn)

12.5.1. North America Gastric Motility Disorder Drugs Market, by Country, 2022 Vs 2030 (in%)

12.5.2. U.S.

12.5.3. Canada

12.5.4. Mexico

 

13. Europe Gastric Motility Disorder Drugs Market Analysis

13.1. Overview

13.1.1. Market Dynamics for North America

13.1.1.1. Drivers

13.1.1.2. Restraints

13.1.1.3. Opportunities

13.1.1.4. Trends

13.2. Europe Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2030(US$ Mn)

13.2.1. Overview

13.2.2. SRC Analysis

13.3. Europe Gastric Motility Disorder Drugs Market, by Indication, 2017-2030(US$ Mn)

13.3.1. Overview

13.3.2. SRC Analysis

13.4. Europe Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2030(US$ Mn)

13.4.1. Overview

13.4.2. SRC Analysis

13.5. Europe Gastric Motility Disorder Drugs Market, by Country, 2017-2030 (US$ Mn)

13.5.1. Europe Gastric Motility Disorder Drugs Market, by Country, 2022 Vs 2030 (in%)

13.5.2. UK

13.5.3. France

13.5.4. Germany

13.5.5. Italy

13.5.6. Spain

13.5.7. Benelux

13.5.8. Russia

13.5.9. Rest of Europe

 

14. Asia Pacific Gastric Motility Disorder Drugs Market Analysis

14.1. Overview

14.1.1. Market Dynamics for North America

14.1.1.1. Drivers

14.1.1.2. Restraints

14.1.1.3. Opportunities

14.1.1.4. Trends

14.2. Asia Pacific Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2030(US$ Mn)

14.2.1. Overview

14.2.2. SRC Analysis

14.3. Asia Pacific Gastric Motility Disorder Drugs Market, by Indication, 2017-2030(US$ Mn)

14.3.1. Overview

14.3.2. SRC Analysis

14.4. Asia Pacific Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2030(US$ Mn)

14.4.1. Overview

14.4.2. SRC Analysis

14.5. Asia Pacific Gastric Motility Disorder Drugs Market, by Country, 2017-2030 (US$ Mn)

14.5.1. Asia Pacific Gastric Motility Disorder Drugs Market, by Country, 2022 Vs 2030 (in%)

14.5.2. China

14.5.3. Japan

14.5.4. India

14.5.5. South Korea

14.5.6. South East Asia

14.5.7. Rest of Asia Pacific

 

15. Latin America Gastric Motility Disorder Drugs Market Analysis

15.1. Overview

15.1.1. Market Dynamics for North America

15.1.1.1. Drivers

15.1.1.2. Restraints

15.1.1.3. Opportunities

15.1.1.4. Trends

15.2. Latin America Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2030(US$ Mn)

15.2.1. Overview

15.2.2. SRC Analysis

15.3. Latin America Gastric Motility Disorder Drugs Market, by Indication, 2017-2030(US$ Mn)

15.3.1. Overview

15.3.2. SRC Analysis

15.4. Latin America Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2030(US$ Mn)

15.4.1. Overview

15.4.2. SRC Analysis

15.5. Latin America Gastric Motility Disorder Drugs Market, by Country, 2017-2030 (US$ Mn)

15.5.1. Latin America Gastric Motility Disorder Drugs Market, by Country, 2022 Vs 2030 (in%)

15.5.2. Brazil

15.5.3. Argentina

15.5.4. Rest of Latin America

 

16. Middle East Gastric Motility Disorder Drugs Market Analysis

16.1. Overview

16.1.1. Market Dynamics for North America

16.1.1.1. Drivers

16.1.1.2. Restraints

16.1.1.3. Opportunities

16.1.1.4. Trends

16.2. Middle East Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2030(US$ Mn)

16.2.1. Overview

16.2.2. SRC Analysis

16.3. Middle East Gastric Motility Disorder Drugs Market, by Indication, 2017-2030(US$ Mn)

16.3.1. Overview

16.3.2. SRC Analysis

16.4. Middle East Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2030(US$ Mn)

16.4.1. Overview

16.4.2. SRC Analysis

16.5. Middle East Gastric Motility Disorder Drugs Market, by Country, 2017-2030 (US$ Mn)

16.5.1. Middle East Gastric Motility Disorder Drugs Market, by Country, 2022 Vs 2030 (in%)

16.5.2. UAE

16.5.3. Saudi Arabia

16.5.4. Rest of Middle East

 

17. Africa Gastric Motility Disorder Drugs Market Analysis

17.1. Overview

17.1.1. Market Dynamics for North America

17.1.1.1. Drivers

17.1.1.2. Restraints

17.1.1.3. Opportunities

17.1.1.4. Trends

17.2. Africa Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2030(US$ Mn)

17.2.1. Overview

17.2.2. SRC Analysis

17.3. Africa Gastric Motility Disorder Drugs Market, by Indication, 2017-2030(US$ Mn)

17.3.1. Overview

17.3.2. SRC Analysis

17.4. Africa Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2030(US$ Mn)

17.4.1. Overview

17.4.2. SRC Analysis

17.5. Africa Gastric Motility Disorder Drugs Market, by Country, 2017-2030 (US$ Mn)

17.5.1. Middle East Gastric Motility Disorder Drugs Market, by Country, 2022 Vs 2030 (in%)

17.5.2. South Africa

17.5.3. Egypt

17.5.4. Rest of Africa

 

18. Company Profiles

18.1. Abbott

18.1.1. Company Overview

18.1.2. Products/Services Portfolio

18.1.3. Geographical Presence

18.1.4. SWOT Analysis

18.1.5. Financial Summary

18.1.5.1. Market Revenue and Net Profit (2019-2022)

18.1.5.2. Business Segment Revenue Analysis

18.1.5.3. Geographical Revenue Analysis

18.2. Janssen Pharmaceuticals NV

18.3. Sun Pharmaceutical Industries Ltd

18.4. Cipla Inc

18.5. Gilead Sciences Inc

18.6. Biogen

18.7. Organon Group of Companies

18.8. AbbVie Inc

18.9. AstraZeneca

18.10. Salix Pharmaceuticals

18.11. Takeda Pharmaceutical Company Ltd

18.12. Pfizer Inc

18.13. Bayer AG

18.14. Others

 

19. Research Methodology

19.1. Research Methodology

19.2. Phase I – Secondary Research

19.3. Phase II – Data Modelling

19.3.1. Company Share Analysis Model

19.3.2. Revenue Based Modelling

19.4. Phase III – Primary Research

19.5. Research Limitations

19.5.1. Assumptions

 

List of Figures

FIG. 1 Global Gastric Motility Disorder Drugs Market: Research Methodology

FIG. 2 Market Size Estimation – Top Down & Bottom Up Approach

FIG. 3 Global Gastric Motility Disorder Drugs Market Segmentation

FIG. 4 Global Gastric Motility Disorder Drugs Market, by Drug Type, 2022 (US$ Mn)

FIG. 5 Global Gastric Motility Disorder Drugs Market, by Indication, 2022 (US$ Mn)

FIG. 6 Global Gastric Motility Disorder Drugs Market, by Distribution Channel, 2022 (US$ Mn)

FIG. 7 Global Gastric Motility Disorder Drugs Market, by Geography, 2022 (US$ Mn)

FIG. 8 Attractive Investment Proposition, by Drug Type, 2022

FIG. 9 Attractive Investment Proposition, by Indication, 2022

FIG. 10 Attractive Investment Proposition, by Distribution Channel, 2022

FIG. 11 Attractive Investment Proposition, by Geography, 2022

FIG. 12 Global Market Share Analysis of Key Gastric Motility Disorder Drugs Market Manufacturers, 2022

FIG. 13 Global Market Positioning of Key Gastric Motility Disorder Drugs Market Manufacturers, 2022

FIG. 14 Global Gastric Motility Disorder Drugs Market Value Contribution, By Drug Type, 2022 & 2030 (Value %)

FIG. 15 Global Gastric Motility Disorder Drugs Market, by Prokinetic Agents Segment, Value, 2017-2030 (US$ Mn)

FIG. 16 Global Gastric Motility Disorder Drugs Market, by Antispasmodic Agents Segment, Value, 2017-2030 (US$ Mn)

FIG. 17 Global Gastric Motility Disorder Drugs Market, by Acid Suppressors Segment, Value, 2017-2030 (US$ Mn)

FIG. 18 Global Gastric Motility Disorder Drugs Market Value Contribution, By Indication, 2022 & 2030 (Value %)

FIG. 19 Global Gastric Motility Disorder Drugs Market, by Gastroparesis, Value, 2017-2030 (US$ Mn)

FIG. 20 Global Gastric Motility Disorder Drugs Market, by Functional Dyspepsia, Value, 2017-2030 (US$ Mn)

FIG. 21 Global Gastric Motility Disorder Drugs Market, by Gastroesophageal Reflux Disease (GERD), Value, 2017-2030 (US$ Mn)

FIG. 22 Global Gastric Motility Disorder Drugs Market, by Irritable Bowel Syndrome (IBS), Value, 2017-2030 (US$ Mn)

FIG. 23 Global Gastric Motility Disorder Drugs Market, by Other Motility Disorders, Value, 2017-2030 (US$ Mn)

FIG. 24 Global Gastric Motility Disorder Drugs Market Value Contribution, By Distribution Channel, 2022 & 2030 (Value %)

FIG. 25 Global Gastric Motility Disorder Drugs Market, by Hospital Pharmacies, Value, 2017-2030 (US$ Mn)

FIG. 26 Global Gastric Motility Disorder Drugs Market, by Retail Pharmacies, Value, 2017-2030 (US$ Mn)

FIG. 27 Global Gastric Motility Disorder Drugs Market, by Online Pharmacies, Value, 2017-2030 (US$ Mn)

FIG. 28 North America Gastric Motility Disorder Drugs Market, 2017-2030 (US$ Mn)

FIG. 29 U.S. Gastric Motility Disorder Drugs Market, 2017-2030 (US$ Mn)

FIG. 30 Canada Gastric Motility Disorder Drugs Market, 2017-2030 (US$ Mn)

FIG. 31 Mexico Gastric Motility Disorder Drugs Market, 2017-2030 (US$ Mn)

FIG. 32 Europe Gastric Motility Disorder Drugs Market, 2017-2030 (US$ Mn)

FIG. 33 Germany Gastric Motility Disorder Drugs Market, 2017-2030 (US$ Mn)

FIG. 34 France Gastric Motility Disorder Drugs Market, 2017-2030 (US$ Mn)

FIG. 35 U.K. Gastric Motility Disorder Drugs Market, 2017-2030 (US$ Mn)

FIG. 36 Italy Gastric Motility Disorder Drugs Market, 2017-2030 (US$ Mn)

FIG. 37 Spain Gastric Motility Disorder Drugs Market, 2017-2030 (US$ Mn)

FIG. 38 Benelux Gastric Motility Disorder Drugs Market, 2017-2030 (US$ Mn)

FIG. 39 Russia Gastric Motility Disorder Drugs Market, 2017-2030 (US$ Mn)

FIG. 40 Rest of Europe Gastric Motility Disorder Drugs Market, 2017-2030 (US$ Mn)

FIG. 41 Asia Pacific Gastric Motility Disorder Drugs Market, 2017-2030 (US$ Mn)

FIG. 42 China Gastric Motility Disorder Drugs Market, 2017-2030 (US$ Mn)

FIG. 43 Japan Gastric Motility Disorder Drugs Market, 2017-2030 (US$ Mn)

FIG. 44 India Gastric Motility Disorder Drugs Market, 2017-2030 (US$ Mn)

FIG. 45 South Korea Gastric Motility Disorder Drugs Market, 2017-2030 (US$ Mn)

FIG. 46 South-East Asia Gastric Motility Disorder Drugs Market, 2017-2030 (US$ Mn)

FIG. 47 Rest of Asia Pacific Gastric Motility Disorder Drugs Market, 2017-2030 (US$ Mn)

FIG. 48 Latin America Gastric Motility Disorder Drugs Market, 2017-2030 (US$ Mn)

FIG. 49 Brazil Gastric Motility Disorder Drugs Market, 2017-2030 (US$ Mn)

FIG. 50 Argentina Gastric Motility Disorder Drugs Market, 2017-2030 (US$ Mn)

FIG. 51 Rest of Latin America Gastric Motility Disorder Drugs Market, 2017-2030 (US$ Mn)

FIG. 52 Middle East Gastric Motility Disorder Drugs Market, 2017-2030 (US$ Mn)

FIG. 53 UAE Gastric Motility Disorder Drugs Market, 2017-2030 (US$ Mn)

FIG. 54 Saudi Arabia Gastric Motility Disorder Drugs Market, 2017-2030 (US$ Mn)

FIG. 55 Rest of Middle East Gastric Motility Disorder Drugs Market, 2017-2030 (US$ Mn)

FIG. 56 Africa Gastric Motility Disorder Drugs Market, 2017-2030 (US$ Mn)

FIG. 57 South Africa Gastric Motility Disorder Drugs Market, 2017-2030 (US$ Mn)

FIG. 58 Egypt Gastric Motility Disorder Drugs Market, 2017-2030 (US$ Mn)

FIG. 59 Rest of Africa Gastric Motility Disorder Drugs Market, 2017-2030 (US$ Mn)

 

List of Tables

TABLE 1 Market Snapshot: Global Gastric Motility Disorder Drugs Market

TABLE 2 Global Gastric Motility Disorder Drugs Market: Market Drivers Impact Analysis

TABLE 3 Global Gastric Motility Disorder Drugs Market: Market Restraints Impact Analysis

TABLE 4 Global Gastric Motility Disorder Drugs Market, by Competitive Benchmarking, 2022

TABLE 5 Global Gastric Motility Disorder Drugs Market, by Geographical Presence Analysis, 2022

TABLE 6 Global Gastric Motility Disorder Drugs Market, by Key Strategies Analysis, 2022

TABLE 7 Global Gastric Motility Disorder Drugs Market, by Prokinetic Agents Segment, By Region, 2017-2022 (US$ Mn)

TABLE 8 Global Gastric Motility Disorder Drugs Market, by Prokinetic Agents Segment, By Region, 2023-2030 (US$ Mn)

TABLE 9 Global Gastric Motility Disorder Drugs Market, by Antispasmodic Agents Segment, By Region, 2017-2022 (US$ Mn)

TABLE 10 Global Gastric Motility Disorder Drugs Market, by Antispasmodic Agents Segment, By Region, 2023-2030 (US$ Mn)

TABLE 11 Global Gastric Motility Disorder Drugs Market, by Acid Suppressors Segment, By Region, 2017-2022 (US$ Mn)

TABLE 12 Global Gastric Motility Disorder Drugs Market, by Acid Suppressors Segment, By Region, 2023-2030 (US$ Mn)

TABLE 13 Global Gastric Motility Disorder Drugs Market, by Gastroparesis, By Region, 2017-2022 (US$ Mn)

TABLE 14 Global Gastric Motility Disorder Drugs Market, by Gastroparesis, By Region, 2023-2030 (US$ Mn)

TABLE 15 Global Gastric Motility Disorder Drugs Market, by Functional Dyspepsia, By Region, 2017-2022 (US$ Mn)

TABLE 16 Global Gastric Motility Disorder Drugs Market, by Functional Dyspepsia, By Region, 2023-2030 (US$ Mn)

TABLE 17 Global Gastric Motility Disorder Drugs Market, by Gastroesophageal Reflux Disease (GERD), By Region, 2017-2022 (US$ Mn)

TABLE 18 Global Gastric Motility Disorder Drugs Market, by Gastroesophageal Reflux Disease (GERD), By Region, 2023-2030 (US$ Mn)

TABLE 19 Global Gastric Motility Disorder Drugs Market, by Irritable Bowel Syndrome (IBS), By Region, 2017-2022 (US$ Mn)

TABLE 20 Global Gastric Motility Disorder Drugs Market, by Irritable Bowel Syndrome (IBS), By Region, 2023-2030 (US$ Mn)

TABLE 21 Global Gastric Motility Disorder Drugs Market, by Other Motility Disorders, By Region, 2017-2022 (US$ Mn)

TABLE 22 Global Gastric Motility Disorder Drugs Market, by Other Motility Disorders, By Region, 2023-2030 (US$ Mn)

TABLE 23 Global Gastric Motility Disorder Drugs Market, by Hospital Pharmacies, By Region, 2017-2022 (US$ Mn)

TABLE 24 Global Gastric Motility Disorder Drugs Market, by Hospital Pharmacies, By Region, 2023-2030 (US$ Mn)

TABLE 25 Global Gastric Motility Disorder Drugs Market, by Retail Pharmacies, By Region, 2017-2022 (US$ Mn)

TABLE 26 Global Gastric Motility Disorder Drugs Market, by Retail Pharmacies, By Region, 2023-2030 (US$ Mn)

TABLE 27 Global Gastric Motility Disorder Drugs Market, by Online Pharmacies, By Region, 2017-2022 (US$ Mn)

TABLE 28 Global Gastric Motility Disorder Drugs Market, by Online Pharmacies, By Region, 2023-2030 (US$ Mn)

TABLE 29 Global Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 30 Global Gastric Motility Disorder Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 31 Global Gastric Motility Disorder Drugs Market, by Indication, 2017-2022 (US$ Mn)

TABLE 32 Global Gastric Motility Disorder Drugs Market, by Indication, 2023-2030 (US$ Mn)

TABLE 33 Global Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 34 Global Gastric Motility Disorder Drugs Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 35 Global Gastric Motility Disorder Drugs Market, by Region, 2017-2022 (US$ Mn)

TABLE 36 Global Gastric Motility Disorder Drugs Market, by Region, 2023-2030 (US$ Mn)

TABLE 37 North America Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 38 North America Gastric Motility Disorder Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 39 North America Gastric Motility Disorder Drugs Market, by Indication, 2017-2022 (US$ Mn)

TABLE 40 North America Gastric Motility Disorder Drugs Market, by Indication, 2023-2030 (US$ Mn)

TABLE 41 North America Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 42 North America Gastric Motility Disorder Drugs Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 43 North America Gastric Motility Disorder Drugs Market, by Country, 2017-2022 (US$ Mn)

TABLE 44 North America Gastric Motility Disorder Drugs Market, by Country, 2023-2030 (US$ Mn)

TABLE 45 United States Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 46 United States Gastric Motility Disorder Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 47 United States Gastric Motility Disorder Drugs Market, by Indication, 2017-2022 (US$ Mn)

TABLE 48 United States Gastric Motility Disorder Drugs Market, by Indication, 2023-2030 (US$ Mn)

TABLE 49 United States Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 50 United States Gastric Motility Disorder Drugs Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 51 Canada Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 52 Canada Gastric Motility Disorder Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 53 Canada Gastric Motility Disorder Drugs Market, by Indication, 2017-2022 (US$ Mn)

TABLE 54 Canada Gastric Motility Disorder Drugs Market, by Indication, 2023-2030 (US$ Mn)

TABLE 55 Canada Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 56 Canada Gastric Motility Disorder Drugs Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 57 Mexico Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 58 Mexico Gastric Motility Disorder Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 59 Mexico Gastric Motility Disorder Drugs Market, by Indication, 2017-2022 (US$ Mn)

TABLE 60 Mexico Gastric Motility Disorder Drugs Market, by Indication, 2023-2030 (US$ Mn)

TABLE 61 Mexico Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 62 Mexico Gastric Motility Disorder Drugs Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 63 Europe Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 64 Europe Gastric Motility Disorder Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 65 Europe Gastric Motility Disorder Drugs Market, by Indication, 2017-2022 (US$ Mn)

TABLE 66 Europe Gastric Motility Disorder Drugs Market, by Indication, 2023-2030 (US$ Mn)

TABLE 67 Europe Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 68 Europe Gastric Motility Disorder Drugs Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 69 Europe Gastric Motility Disorder Drugs Market, by Country, 2017-2022 (US$ Mn)

TABLE 70 Europe Gastric Motility Disorder Drugs Market, by Country, 2023-2030 (US$ Mn)

TABLE 71 Germany Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 72 Germany Gastric Motility Disorder Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 73 Germany Gastric Motility Disorder Drugs Market, by Indication, 2017-2022 (US$ Mn)

TABLE 74 Germany Gastric Motility Disorder Drugs Market, by Indication, 2023-2030 (US$ Mn)

TABLE 75 Germany Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 76 Germany Gastric Motility Disorder Drugs Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 77 France Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 78 France Gastric Motility Disorder Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 79 France Gastric Motility Disorder Drugs Market, by Indication, 2017-2022 (US$ Mn)

TABLE 80 France Gastric Motility Disorder Drugs Market, by Indication, 2023-2030 (US$ Mn)

TABLE 81 France Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 82 France Gastric Motility Disorder Drugs Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 83 United Kingdom Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 84 United Kingdom Gastric Motility Disorder Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 85 United Kingdom Gastric Motility Disorder Drugs Market, by Indication, 2017-2022 (US$ Mn)

TABLE 86 United Kingdom Gastric Motility Disorder Drugs Market, by Indication, 2023-2030 (US$ Mn)

TABLE 87 United Kingdom Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 88 United Kingdom Gastric Motility Disorder Drugs Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 89 Italy Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 90 Italy Gastric Motility Disorder Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 91 Italy Gastric Motility Disorder Drugs Market, by Indication, 2017-2022 (US$ Mn)

TABLE 92 Italy Gastric Motility Disorder Drugs Market, by Indication, 2023-2030 (US$ Mn)

TABLE 93 Italy Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 94 Italy Gastric Motility Disorder Drugs Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 95 Spain Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 96 Spain Gastric Motility Disorder Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 97 Spain Gastric Motility Disorder Drugs Market, by Indication, 2017-2022 (US$ Mn)

TABLE 98 Spain Gastric Motility Disorder Drugs Market, by Indication, 2023-2030 (US$ Mn)

TABLE 99 Spain Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 100 Spain Gastric Motility Disorder Drugs Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 101 Benelux Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 102 Benelux Gastric Motility Disorder Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 103 Benelux Gastric Motility Disorder Drugs Market, by Indication, 2017-2022 (US$ Mn)

TABLE 104 Benelux Gastric Motility Disorder Drugs Market, by Indication, 2023-2030 (US$ Mn)

TABLE 105 Benelux Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 106 Benelux Gastric Motility Disorder Drugs Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 107 Russia Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 108 Russia Gastric Motility Disorder Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 109 Russia Gastric Motility Disorder Drugs Market, by Indication, 2017-2022 (US$ Mn)

TABLE 110 Russia Gastric Motility Disorder Drugs Market, by Indication, 2023-2030 (US$ Mn)

TABLE 111 Russia Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 112 Russia Gastric Motility Disorder Drugs Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 113 Rest of Europe Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 114 Rest of Europe Gastric Motility Disorder Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 115 Rest of Europe Gastric Motility Disorder Drugs Market, by Indication, 2017-2022 (US$ Mn)

TABLE 116 Rest of Europe Gastric Motility Disorder Drugs Market, by Indication, 2023-2030 (US$ Mn)

TABLE 117 Rest of Europe Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 118 Rest of Europe Gastric Motility Disorder Drugs Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 119 Asia Pacific Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 120 Asia Pacific Gastric Motility Disorder Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 121 Asia Pacific Gastric Motility Disorder Drugs Market, by Indication, 2017-2022 (US$ Mn)

TABLE 122 Asia Pacific Gastric Motility Disorder Drugs Market, by Indication, 2023-2030 (US$ Mn)

TABLE 123 Asia Pacific Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 124 Asia Pacific Gastric Motility Disorder Drugs Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 125 China Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 126 China Gastric Motility Disorder Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 127 China Gastric Motility Disorder Drugs Market, by Indication, 2017-2022 (US$ Mn)

TABLE 128 China Gastric Motility Disorder Drugs Market, by Indication, 2023-2030 (US$ Mn)

TABLE 129 China Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 130 China Gastric Motility Disorder Drugs Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 131 Japan Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 132 Japan Gastric Motility Disorder Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 133 Japan Gastric Motility Disorder Drugs Market, by Indication, 2017-2022 (US$ Mn)

TABLE 134 Japan Gastric Motility Disorder Drugs Market, by Indication, 2023-2030 (US$ Mn)

TABLE 135 Japan Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 136 Japan Gastric Motility Disorder Drugs Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 137 India Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 138 India Gastric Motility Disorder Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 139 India Gastric Motility Disorder Drugs Market, by Indication, 2017-2022 (US$ Mn)

TABLE 140 India Gastric Motility Disorder Drugs Market, by Indication, 2023-2030 (US$ Mn)

TABLE 141 India Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 142 India Gastric Motility Disorder Drugs Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 143 South Korea Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 144 South Korea Gastric Motility Disorder Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 145 South Korea Gastric Motility Disorder Drugs Market, by Indication, 2017-2022 (US$ Mn)

TABLE 146 South Korea Gastric Motility Disorder Drugs Market, by Indication, 2023-2030 (US$ Mn)

TABLE 147 South Korea Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 148 South Korea Gastric Motility Disorder Drugs Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 149 South-East Asia Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 150 South-East Asia Gastric Motility Disorder Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 151 South-East Asia Gastric Motility Disorder Drugs Market, by Indication, 2017-2022 (US$ Mn)

TABLE 152 South-East Asia Gastric Motility Disorder Drugs Market, by Indication, 2023-2030 (US$ Mn)

TABLE 153 South-East Asia Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 154 South-East Asia Gastric Motility Disorder Drugs Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 155 Rest of Asia Pacific Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 156 Rest of Asia Pacific Gastric Motility Disorder Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 157 Rest of Asia Pacific Gastric Motility Disorder Drugs Market, by Indication, 2017-2022 (US$ Mn)

TABLE 158 Rest of Asia Pacific Gastric Motility Disorder Drugs Market, by Indication, 2023-2030 (US$ Mn)

TABLE 159 Rest of Asia Pacific Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 160 Rest of Asia Pacific Gastric Motility Disorder Drugs Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 161 Latin America Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 162 Latin America Gastric Motility Disorder Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 163 Latin America Gastric Motility Disorder Drugs Market, by Indication, 2017-2022 (US$ Mn)

TABLE 164 Latin America Gastric Motility Disorder Drugs Market, by Indication, 2023-2030 (US$ Mn)

TABLE 165 Latin America Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 166 Latin America Gastric Motility Disorder Drugs Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 167 Brazil Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 168 Brazil Gastric Motility Disorder Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 169 Brazil Gastric Motility Disorder Drugs Market, by Indication, 2017-2022 (US$ Mn)

TABLE 170 Brazil Gastric Motility Disorder Drugs Market, by Indication, 2023-2030 (US$ Mn)

TABLE 171 Brazil Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 172 Brazil Gastric Motility Disorder Drugs Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 173 Argentina Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 174 Argentina Gastric Motility Disorder Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 175 Argentina Gastric Motility Disorder Drugs Market, by Indication, 2017-2022 (US$ Mn)

TABLE 176 Argentina Gastric Motility Disorder Drugs Market, by Indication, 2023-2030 (US$ Mn)

TABLE 177 Argentina Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 178 Argentina Gastric Motility Disorder Drugs Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 179 Rest of Latin America Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 180 Rest of Latin America Gastric Motility Disorder Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 181 Rest of Latin America Gastric Motility Disorder Drugs Market, by Indication, 2017-2022 (US$ Mn)

TABLE 182 Rest of Latin America Gastric Motility Disorder Drugs Market, by Indication, 2023-2030 (US$ Mn)

TABLE 183 Rest of Latin America Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 184 Rest of Latin America Gastric Motility Disorder Drugs Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 185 Middle East Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 186 Middle East Gastric Motility Disorder Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 187 Middle East Gastric Motility Disorder Drugs Market, by Indication, 2017-2022 (US$ Mn)

TABLE 188 Middle East Gastric Motility Disorder Drugs Market, by Indication, 2023-2030 (US$ Mn)

TABLE 189 Middle East Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 190 Middle East Gastric Motility Disorder Drugs Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 191 UAE Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 192 UAE Gastric Motility Disorder Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 193 UAE Gastric Motility Disorder Drugs Market, by Indication, 2017-2022 (US$ Mn)

TABLE 194 UAE Gastric Motility Disorder Drugs Market, by Indication, 2023-2030 (US$ Mn)

TABLE 195 UAE Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 196 UAE Gastric Motility Disorder Drugs Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 197 Saudi Arabia Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 198 Saudi Arabia Gastric Motility Disorder Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 199 Saudi Arabia Gastric Motility Disorder Drugs Market, by Indication, 2017-2022 (US$ Mn)

TABLE 200 Saudi Arabia Gastric Motility Disorder Drugs Market, by Indication, 2023-2030 (US$ Mn)

TABLE 201 Saudi Arabia Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 202 Saudi Arabia Gastric Motility Disorder Drugs Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 203 Rest of Middle East Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 204 Rest of Middle East Gastric Motility Disorder Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 205 Rest of Middle East Gastric Motility Disorder Drugs Market, by Indication, 2017-2022 (US$ Mn)

TABLE 206 Rest of Middle East Gastric Motility Disorder Drugs Market, by Indication, 2023-2030 (US$ Mn)

TABLE 207 Rest of Middle East Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 208 Rest of Middle East Gastric Motility Disorder Drugs Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 209 Africa Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 210 Africa Gastric Motility Disorder Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 211 Africa Gastric Motility Disorder Drugs Market, by Indication, 2017-2022 (US$ Mn)

TABLE 212 Africa Gastric Motility Disorder Drugs Market, by Indication, 2023-2030 (US$ Mn)

TABLE 213 Africa Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 214 Africa Gastric Motility Disorder Drugs Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 215 South Africa Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 216 South Africa Gastric Motility Disorder Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 217 South Africa Gastric Motility Disorder Drugs Market, by Indication, 2017-2022 (US$ Mn)

TABLE 218 South Africa Gastric Motility Disorder Drugs Market, by Indication, 2023-2030 (US$ Mn)

TABLE 219 South Africa Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 220 South Africa Gastric Motility Disorder Drugs Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 221 Egypt Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 222 Egypt Gastric Motility Disorder Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 223 Egypt Gastric Motility Disorder Drugs Market, by Indication, 2017-2022 (US$ Mn)

TABLE 224 Egypt Gastric Motility Disorder Drugs Market, by Indication, 2023-2030 (US$ Mn)

TABLE 225 Egypt Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 226 Egypt Gastric Motility Disorder Drugs Market, by Distribution Channel, 2023-2030 (US$ Mn)

TABLE 227 Rest of Africa Gastric Motility Disorder Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 228 Rest of Africa Gastric Motility Disorder Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 229 Rest of Africa Gastric Motility Disorder Drugs Market, by Indication, 2017-2022 (US$ Mn)

TABLE 230 Rest of Africa Gastric Motility Disorder Drugs Market, by Indication, 2023-2030 (US$ Mn)

TABLE 231 Rest of Africa Gastric Motility Disorder Drugs Market, by Distribution Channel, 2017-2022 (US$ Mn)

TABLE 232 Rest of Africa Gastric Motility Disorder Drugs Market, by Distribution Channel, 2023-2030 (US$ Mn)

Frequently Asked Questions

What is the current size of the global gastric motility disorder drugs market?

The global gastric motility disorder drugs market was valued at USD XX million in 2022.8

What is the expected growth rate of the gastric motility disorder drugs market between 2023 and 2030?

The gastric motility disorder drugs market is expected to grow at a CAGR of 4.9% between 2023 and 2030, reaching USD XX Million in 2030.

Which segment is leading the market share in terms of drug type?

The prokinetic agents segment is the leading category by drug type, holding over 40% share in value in 2022.

Which indication segment governs the global demand for gastric motility disorder drugs?

Gastroparesis governs the global demand for gastric motility disorder drugs, holding a massive market share of over 30% in 2022.

Which distribution channel segment will post the highest CAGR in the forecast period?

The retail and online pharmacies segment will post the highest CAGR over the projection period.

Which region is fueling the growth of the gastric motility disorder drugs industry?

North America is fueling the rapid growth of the gastric motility disorder drugs industry, with over one-third of its share in 2022.

Who are the major players in the global gastric motility disorder drugs market?

The top players include Abbott, Janssen Pharmaceuticals NV, Sun Pharmaceutical Industries Ltd, Cipla Inc, Gilead Sciences Inc, Biogen, Organon Group of Companies, AbbVie Inc, AstraZeneca, Salix Pharmaceuticals, Takeda Pharmaceutical Company Ltd, Pfizer Inc, Bayer AG, and Others.

What are the major market drivers of the gastric motility disorder drugs industry?

The major market drivers of the gastric motility disorder drugs industry include the increasing prevalence of gastric motility disorders, advancements in diagnostic techniques, and the potential for innovative biologic therapies.

What are the major market restraints of the gastric motility disorder drugs industry?

The major market restraints of the gastric motility disorder drugs industry comprise limited treatment options and regulatory approval challenges due to the complexity of the disorders and small patient populations.

What are the major market opportunities of the gastric motility disorder drugs industry?

The major market opportunities in the gastric motility disorder drugs industry encompass biologic therapies and personalized medicine approaches, as well as expansion into emerging markets with changing demographics and improved healthcare infrastructure.

Inulin Market

Published:
Report ID: 11192

Drug Discovery Market

Published:
Report ID: 38270

Neurotrophic Keratitis Treatment Market

Published:
Report ID: 33425

Japan’s Pharmacy Automation Market

Published:
Report ID: 37511

Sterile Active Pharmaceutical Ingredient Market

Published:
Report ID: 37476

Organ Preservation Solutions Market

Published:
Report ID: 37472

Middle East and Africa Veterinary Vaccines Market

Published:
Report ID: 37309

Asia Pacific Stem Cell Therapy Market

Published:
Report ID: 37280

US Active Pharmaceutical Ingredient (API) Market

Published:
Report ID: 37221

Cancer Supportive Care Market

Published:
Report ID: 1901

Middle East and Africa Radiopharmaceuticals Market

Published:
Report ID: 37164

Temperature Controlled Pharma Packaging Solutions Market

Published:
Report ID: 20599

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN